Sparrow Pharmaceuticals Presents New Pharmacological Data on HSD-1 Inhibitor SPI-62 at the 2022 Annual European Congress of Rheumatology
Sparrow Pharmaceuticals , an emerging, clinical-stage biopharmaceutical company developing novel, targeted therapies to address unmet needs in both rheumatology and endocrinology, today presented new animal model data during an in-person poster session titled, Toward Safer Glucocorticoid Therapy of Polymyalgia Rheumatica at the 2022 Annual European Congress of Rheumatology (EULAR 2022).